Resolving the Opioid Crisis in the United States: A Time-series Analysis on the Efficacy of Major Federal Policies

Authors

  • Alina Mindy Zheng Allen High School, Texas, USA

DOI:

https://doi.org/10.54097/yq6a9711

Keywords:

Opioid crisis; Opioid policy; Respiratory depression; Time-series analysis.

Abstract

The opioid crisis has emerged as one of the most pressing public health emergencies in the United States, with overdose deaths increasing more than tenfold since 1999. This study investigates the impact of major federal policies on opioid-related harms, with a focus on respiratory depression, the leading cause of opioid overdose mortality. Using data from the FDA Adverse Event Reporting System (FAERS) between 2015 and 2025, the analysis combines opioid distribution and adverse event data into a monthly time series, incorporating key policy interventions as structural breaks. The study evaluates both short-term policy effects and long-term trends through forecasting models like SARIMAX, Prophet, and LSTM. Results indicate that opioid distribution strongly predicts adverse outcomes, with a one to two-month lag, reinforcing the link between prescription practices and patient adverse effects. Policies like the 2016 CDC Opioid Prescribing Guidelines and the 2018 SUPPORT Act produced measurable reductions in adverse event growth, while others had limited statistical significance. The findings emphasize that resolving an epidemic requires a comprehensive strategy that implements both supply control through proper regulations and market control through patient-centered education and harm reduction initiatives.

Downloads

Download data is not yet available.

References

[1] Kolodny, A. How FDA failures contributed to the opioid crisis. AMA Journal of Ethics, 2020, 22(8), 743–750. DOI: https://doi.org/10.1001/amajethics.2020.743

[2] Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic. Overdose Prevention. Atlanta, GA: CDC; 2025.

[3] National Institute on Drug Abuse. Drug overdose deaths: Facts and figures. Bethesda, MD: NIDA; 2024.

[4] Williams, E., & Saunders, H. Opioid deaths fell in mid-2023, but progress is uneven and future trends are uncertain. KFF Health Policy Analysis. KFF; 2024.

[5] Community Anti-Drug Coalitions of America (CADCA). The Comprehensive Addiction and Recovery Act (CARA). CADCA; 2023.

[6] Medicaid. Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act: Section 1003. Washington, DC: Medicaid.gov; 2022.

[7] Rudolph, K. E., Kinnard, E. N., Aguirre, A. R., Goin, D. E., Feelemyer, J., Fink, D., et al. The relative economy and drug overdose deaths. Epidemiology (Cambridge, Mass), 2020, 31(4), 551–558. DOI: https://doi.org/10.1097/EDE.0000000000001199

[8] Bateman, J. T., Saunders, S. E., & Levitt, E. S. Understanding and countering opioid-induced respiratory depression. British Journal of Pharmacology, 2021, 180(7), 813–828. DOI: https://doi.org/10.1111/bph.15580

[9] Dowell, D., Haegerich, T. M., & Chou, R. CDC guideline for prescribing opioids for chronic pain. MMWR Recommendations and Reports, 2019, 65(1), 1–49. DOI: https://doi.org/10.15585/mmwr.rr6501e1

[10] Pollack, R. Supporting patients and caregivers facing substance use disorders. AHA News. Washington, DC: American Hospital Association; 2025.

[11] American Immigration Council. Fentanyl smuggling: Most seizures occur at ports of entry where U.S. citizens are the primary smugglers. Washington, DC: American Immigration Council; 2025.

[12] Dowell, D., Ragan, K., Jones, C., Baldwin, G., & Chou, R. CDC clinical practice guideline for prescribing opioids for pain. MMWR Recommendations and Reports, 2022, 71(3), 1–95. DOI: https://doi.org/10.15585/mmwr.rr7103a1

[13] National Academies of Sciences, Engineering, and Medicine. Introduction. Washington, DC: National Academies Press (U.S.); 2023.

[14] Connery, L. Introduction of the Modernizing Opioid Treatment Access Act. MATTERS Network. 2023.

[15] Strickler, G. K., Kreiner, P. W., Halpin, J. F., Doyle, E., & Paulozzi, L. J. Opioid prescribing behaviors—Prescription Behavior Surveillance System, 11 States, 2010–2016. MMWR Surveillance Summaries, 2020, 69(1), 1–14. DOI: https://doi.org/10.15585/mmwr.ss6901a1

[16] U.S. Food and Drug Administration. Changes to opioid prescribing information regarding long-term use. Silver Spring, MD: U.S. FDA; 2025.

[17] Meara, E., Horwitz, J. R., Powell, W., McClelland, L., Zhou, W., & O’Malley, A. J., et al. State legal restrictions and prescription-opioid use among disabled adults. New England Journal of Medicine, 2016, 375(1), 44–53. DOI: https://doi.org/10.1056/NEJMsa1514387

[18] Centers for Disease Control and Prevention. 2022 CDC clinical practice guideline at a glance. Overdose Prevention. CDC; 2024.

[19] U.S. Drug Enforcement Administration (DEA). One pill can kill. DEA; 2023.

[20] National Institute on Drug Abuse (NIDA). Medications for opioid use disorder. NIDA; 2025.

[21] MATTERS Learning Collaborative (LC). Efficacy of harm reduction. MATTERS Network. 2025.

Downloads

Published

27-12-2025

How to Cite

Zheng, A. M. (2025). Resolving the Opioid Crisis in the United States: A Time-series Analysis on the Efficacy of Major Federal Policies. Highlights in Business, Economics and Management, 65, 417-425. https://doi.org/10.54097/yq6a9711